Updated:
Alpha Cognition
Listed on the NASDAQ: ACOG | Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served...
Alpha Cognition
Listed on the NASDAQ: ACOG | Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration.
General information
Firm type
Asset Manager
Frequently asked questions
How is Alpha Cognition funded?
As a publicly traded company, Alpha Cognition funds operations through equity sales in the capital markets. It does not raise capital through limited partner commitments, a fund-of-funds model, or family-office allocations. The burn rate is tied to regulatory and clinical-development milestones, with no diversified investment portfolio to offset risk.
Does Alpha Cognition have a investment portfolio or private-equity mandate?
No. The company holds no disclosed minority positions in portfolio companies, real-asset interests, or fund-of-fund commitments. Its balance sheet reflects cash reserves and operational assets associated with a pre-revenue biotech development program, not an investment portfolio.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: